2-[(3-cyclopropyl-4,4-dimethyl-2-oxo-quinazolin-1-yl)methyl]-N'-hydroxy-1-isopentyl-benzimidazole-5-carboxamidine | 1243324-62-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 2-[(3-cyclopropyl-4,4-dimethyl-2-oxo-quinazolin-1-yl)methyl]-N'-hydroxy-1-isopentyl-benzimidazole-5-carboxamidine
• 英文别名: 2-[(3-cyclopropyl-4,4-dimethyl-2-oxoquinazolin-1-yl)methyl]-N'-hydroxy-1-(3-methylbutyl)benzimidazole-5-carboximidamide
• CAS: 1243324-62-0
• 化学式: C₂₇H₃₄N₆O₂
• 分子量: 474.606
• InChiKey: FVHQVFPMBZLVOO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  35
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  100
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS<br/>[FR] POLYTHÉRAPIE POUR TRAITER UN PARAMYXOVIRUS
  申请人：ALIOS BIOPHARMA INC

  公开号：WO2016022464A1

  公开（公告）日：2016-02-11

  Disclosed herein are a combination of compounds and methods of using the combination compounds for ameliorating, treating and/or preventing a paramyxovirus viral infection.

  本文披露了一种化合物组合以及使用该化合物组合来改善、治疗和/或预防副黏病毒感染的方法。
• [EN] BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS ANTIVARAL AGENTS<br/>[FR] DÉRIVÉS DE BENZIMIDAZOLE ET LEUR UTILISATION COMME AGENTS ANTIVIRAUX
  申请人：ASTRAZENECA UK LTD

  公开号：WO2010103306A1

  公开（公告）日：2010-09-16

  The invention provides compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are as defined in the specification, and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are useful in the treatment of respiratory syncytial virus (RSV).

  该发明提供了以下化合物的公式(I)：其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11和R12如规范中所定义，并且其光学异构体、拉丁酸盐和互变异构体，以及其药学上可接受的盐；以及它们的制备方法、含有它们的药物组合物以及它们在治疗中的使用。这些化合物在呼吸道合胞病毒（RSV）的治疗中很有用。
• NOVEL COMPOUNDS 660
  申请人：Blade Helen

  公开号：US20100278835A1

  公开（公告）日：2010-11-04

  The invention provides compounds of formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 and R 12 are as defined in the specification, and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are useful in the treatment of respiratory syncytial virus (RSV).

  本发明提供了式(I)的化合物，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11和R12如规范中所定义，以及其光学异构体、消旋体和互变异构体，以及其药学上可接受的盐；以及它们的制备方法，含有它们的制药组合物以及它们在治疗中的应用。这些化合物在呼吸道合胞病毒(RSV)的治疗中是有用的。
• COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS
  申请人：Alios Biopharma, Inc.

  公开号：EP3177299A1

  公开（公告）日：2017-06-14